Today: 10 March 2026
Browse Category

Earnings Reports 9 January 2026 - 10 January 2026

P&G stock in focus after Crest toothpaste label change — what to watch before Jan. 22 earnings

P&G stock in focus after Crest toothpaste label change — what to watch before Jan. 22 earnings

Procter & Gamble will change Kid’s Crest toothpaste packaging after Texas officials said label artwork encouraged unsafe fluoride use by children. The rollout began Jan. 1 and must last five years. P&G shares closed up 0.24% at $141.87, then slipped 0.17% after hours. Investors await the Jan. 22 earnings call for updates on volumes, pricing, and regulatory scrutiny.
Spotify stock dips after broker target cuts — what to watch before SPOT earnings

Spotify stock dips after broker target cuts — what to watch before SPOT earnings

Spotify shares fell 2.6% to $539.37 Friday after Guggenheim and UBS cut their price targets but kept Buy ratings. The company launched a new podcast studio in Los Angeles and projected podcasts will add $10 billion in value over five years. Investors are watching for signs Spotify can grow revenue without losing subscribers. Fourth-quarter results are due Feb. 10.
JPMorgan Chase stock slips after hours as Apple Card switch sharpens focus on next week’s earnings

JPMorgan Chase stock slips after hours as Apple Card switch sharpens focus on next week’s earnings

JPMorgan Chase shares slipped 0.2% to $329.19 in after-hours trading Friday after the bank agreed to take over the Apple Card from Goldman Sachs, booking a $2.2 billion provision for credit losses. The transition is expected to take up to 24 months, pending regulatory approval. JPMorgan will report earnings Tuesday, as investors watch for signs of rising credit costs and trading trends.
Rocket Lab stock rebounds, holds after-hours bid as RKLB traders weigh insider sales and earnings clock

Rocket Lab stock rebounds, holds after-hours bid as RKLB traders weigh insider sales and earnings clock

Rocket Lab shares closed up 2.1% Friday to $84.85 and edged higher after hours. SEC filings showed CFO Adam Spice and COO Frank Klein sold shares last week under pre-set plans. Investors await fourth-quarter results, expected in late February. The company recently secured an $816 million contract to build missile-warning satellites.
AMD stock dips after hours as focus shifts from CES to the next catalysts

AMD stock dips after hours as focus shifts from CES to the next catalysts

AMD shares fell 0.7% to $203.17 in after-hours trading Friday, despite the PHLX semiconductor index hitting a record as the S&P 500 closed at an all-time high. The stock moved between $202.88 and $207.27 during the session, with about 24.1 million shares traded. Investors are awaiting AMD’s upcoming results and U.S. inflation data due January 13.
Palantir stock ticks higher after hours as jobs data cools and Feb. 2 earnings loom

Palantir stock ticks higher after hours as jobs data cools and Feb. 2 earnings loom

Palantir Technologies shares rose 0.3% to $177.49 in after-hours trading Friday, following a regular session with 31.2 million shares traded. The move came as U.S. payrolls rose by 50,000 in December, missing forecasts, while the jobless rate fell to 4.4%. Palantir remains below its 50-day moving average of $180.83 and well under its 52-week high of $207.52. The company’s next earnings report is expected Feb. 2.
Alphabet (GOOG) stock ticks up after-hours as Google sets Feb. 4 earnings call, CEO sale disclosed

Alphabet (GOOG) stock ticks up after-hours as Google sets Feb. 4 earnings call, CEO sale disclosed

Alphabet Class C shares rose about 1% to $329.14 in after-hours trading Friday. CEO Sundar Pichai sold 32,500 Class C shares for roughly $10.4 million on Jan. 7, leaving him with over 2.2 million. The company reports quarterly results Feb. 4. EU regulators are expected to rule by Feb. 10 on Alphabet’s $32 billion Wiz acquisition.
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis Biotherapeutics shares fell 5.3% to $28.29 Friday after an early surge, tracking a shift in rate expectations following a soft U.S. jobs report. Broader biotech indexes rose. Investors are watching for Arcutis’ next earnings on Feb. 24 and an FDA decision on ZORYVE for children by June 29. The Fed’s late-January meeting remains a key focus for traders.
1 125 126 127 128 129 227
Go toTop